A detailed history of Woodline Partners LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 4,340,340 shares of TVTX stock, worth $74.4 Million. This represents 0.55% of its overall portfolio holdings.

Number of Shares
4,340,340
Previous 1,276,878 239.92%
Holding current value
$74.4 Million
Previous $10.5 Million 478.57%
% of portfolio
0.55%
Previous 0.11%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.89 - $15.21 $24.2 Million - $46.6 Million
3,063,462 Added 239.92%
4,340,340 $60.7 Million
Q2 2024

Aug 14, 2024

BUY
$5.26 - $8.28 $6.72 Million - $10.6 Million
1,276,878 New
1,276,878 $10.5 Million
Q4 2023

Feb 14, 2024

SELL
$5.44 - $9.5 $8.24 Million - $14.4 Million
-1,513,944 Reduced 70.4%
636,621 $5.72 Million
Q3 2023

Nov 14, 2023

BUY
$7.64 - $17.25 $8.48 Million - $19.2 Million
1,110,269 Added 106.73%
2,150,565 $19.2 Million
Q2 2023

Aug 14, 2023

SELL
$15.3 - $22.61 $6.11 Million - $9.03 Million
-399,403 Reduced 27.74%
1,040,296 $16 Million
Q1 2023

May 15, 2023

BUY
$17.82 - $22.89 $23.9 Million - $30.7 Million
1,342,791 Added 1385.63%
1,439,699 $32.4 Million
Q4 2022

Feb 14, 2023

SELL
$18.47 - $26.14 $3.16 Million - $4.48 Million
-171,267 Reduced 63.86%
96,908 $2.04 Million
Q3 2022

Nov 14, 2022

BUY
$22.91 - $28.63 $6.14 Million - $7.68 Million
268,175 New
268,175 $6.61 Million
Q4 2021

Feb 14, 2022

SELL
$24.34 - $31.17 $3.55 Million - $4.55 Million
-145,918 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$12.98 - $25.03 $1.89 Million - $3.65 Million
145,918 New
145,918 $3.54 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.1B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.